Showing 126–145 of 145 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Antonio Lombardi, Fran Pappas, Paul Bruinenberg, Jerry Nedelman, Rajneesh Taneja, et al.
… antibiotic under clinical development for the treatment of tuberculosis. Preclinical data indicate potent antituberculosis activity and a potentially improved safety profile over linezolid. In a single-ascending dose study and a multiple-ascending dose study in 114 healthy adult…
Hao T Duong, Cuong D Do, Donn J Colby, Todd M Pollack
…gher BMI and alcohol use, while food insecurity, history of tuberculosis, advanced clinical stages, and TDF-based regimens were negatively associated. Older age was linked to poorer HRQOL outcomes. These findings highlight the effectiveness of ART in improving HRQOL while also re…
R Perumal, S Pillay, N Bagratee, J Tulsi, N Naidu, et al.
BACKGROUND: Many of the 150 million global TB survivors continue to experience chronic respiratory problems as TB-related anatomical and functional deficits often persist beyond treatment. METHODS: Individuals who completed TB treatment for pulmonary TB in the Improving Retreatme…
J Shenje, G Maartens, L Moran, Y Cramer, J D L Rios, et al.
<sec><title>BACKGROUND</title>Bedaquiline and delamanid are key drugs in the treatment of multidrug-resistant TB. It is unclear whether HIV affects the pharmacokinetics of bedaquiline and delamanid.</sec><sec><title>METHODS</title>Participants with multidrug-resistant TB were ran…
D Mudzengi, S Mashatole, Q Xiang, C Adrion, N Glover, et al.
**BACKGROUND:** Newer oxazolidinones will be required to advance regimens in pan-TB indications. The addition of host-directed agents may help promote the recovery of lung function during TB treatment and prevent post-TB lung disease. **METHODS:** The panTB-HM trial assesses the…
Alexander C Schmidt, Lee Fairlie, Elizabeth Hellström, Angelique Luabeya Kany Kany, Keren Middelkoop, et al.
**BACKGROUND:** In a previous phase 2 trial, bacille Calmette-Guérin (BCG) revaccination was not shown to provide protection from primaryinfection but prevented sustainedinfection, defined by an initial conversion on a QuantiFERON-TB (QFT) test (an interferon-release assay) …
Simon E Koele, Norbert Heinrich, Veronique R De Jager, Julia Dreisbach, Patrick P J Phillips, et al.
**INTRODUCTION:** BTZ-043 is a first-in-class benzothiazinone for the treatment of TB with demonstrated early bactericidal activity. BTZ-043 is metabolized into two major metabolites: M1 and M2. The aim of this study was to characterize the pharmacokinetics (PK) and early exposur…
Nusrat Shafiq, Ashok Kumar, Vikram Vohra, Gopal Krishan Khuller, Manjula Singh, et al.
**BACKGROUND:** Clofazimine, an antimycobacterial agent, has demonstrated efficacy in reducing the treatment duration for MDR TB. **OBJECTIVES:** To determine whether a 16 week clofazimine-based regimen is non-inferior to the standard 24 week regimen for drug-susceptible pulmona…
Julie Huynh, Chishala Chabala, Suvasini Sharma, Louise Choo, Varinder Singh, et al.
…conditional recommendation that 6 months of intensified antituberculosis therapy (ATT) could be used as an alternative for drug-susceptible TBM. However, this has never been evaluated in a randomised clinical trial. Trials evaluating ATT shortening regimens using high-dose rifamp…
Grace Montepiedra, Lisa Aaron, Gerhard Theron, Katie McCarthy, Sarah Bradford, et al.
**BACKGROUND:** TB APPRISE (IMPAACT P1078), a Phase IV randomized, multi-country non-inferiority trial assessing the safety of 28 weeks of isoniazid preventive therapy (IPT) initiated during pregnancy (immediate IPT) versus deferring to week 12 postpartum (deferred IPT) in people…
Elizabeth Mackay, Gareth Platt, Charles A Peloquin, Meredith B Brooks, Julia M Coit, et al.
… Variability in the pharmacokinetics (PK) of first-line antituberculosis drugs (rifampicin [RIF], isoniazid [INH], and pyrazinamide [PZA]) is high and may be influenced by pharmacogenetic polymorphism. We performed a pharmacogenetic substudy in 90 participants with PK data from t…
Ramon Andrade de Souza, Florisneide Rodrigues Barreto, Carla Cristina Oliveira de Jesus Lima, Marcio Santos da Natividade, Carlos Antônio de Souza Teles Santos, et al.
**BACKGROUND:** Can vaccination with Bacille Calmette-Guérin prevent clinical progression of COVID-19? Data from the BCG-REVAC trial was archived in a database, creating an excellent opportunity to link it to notified cases of COVID-19 to evaluate the efficacy of BCG against…
Julie Odgaard Vedel, Oides Furtado, Laerte Lima Almeida, Jailson Sydenei Dias Martins, Sanne Møller Thysen, et al.
**BACKGROUND:** A correct vaccination technique is important for developing BCG scars. Having a BCG scar is associated with lower mortality among BCG-vaccinated children. **AIM:** To compare BCG-scar prevalences among children vaccinated before and after refresher training in BC…
Meena Chandu, Rohit Bhatia, Manish Modi, Ritu Shree, Imnameren Longkumer, et al.
**BACKGROUND:** Cerebral infarction is a frequent and serious complication of tuberculous meningitis (TBM), contributing substantially to morbidity and mortality. Moreover, studies on infarct patterns and associated factors/predictors remain limited in TBM. ACT-TBM trial (Aspirin…
Simon E Koele, Krista Stoycheva, Cyprian Mtweve, Christina Manyama, Stellah Mpagama, et al.
**INTRODUCTION:** Many drugs for the treatment of TB prolong the QTc interval, which is associated with an increased risk of developing a life-threatening arrhythmia known as torsades de pointes. Sutezolid and delpazolid are novel oxazolidinones with demonstrated bactericidal act…
David B Meya, Fiona V Cresswell, Biyue Dai, Nicole Engen, Kogieleum Naidoo, et al.
**BACKGROUND:** Tuberculous meningitis is often lethal, and many survivors have disabilities despite antimicrobial treatment and adjunctive glucocorticoid therapy. Standard-dose rifampin has limited central nervous system penetration. Whether high-dose rifampin could improve surv…
Jose M Calderin, Juan Eduardo Resendiz-Galvan, Noha Abdelgawad, Angharad Davis, Cari Stek, et al.
**BACKGROUND:** Dexamethasone is recommended as adjunctive therapy for tuberculous meningitis (TBM). Co-administration with rifampicin is expected to reduce dexamethasone exposure in TBM, an effect that may be more pronounced with the higher rifampicin doses currently being evalu…
Felicia C Chow, Paddy Kafeero, Maria Nakimbugwe, Anthony Ssemaganda, Colman Tayebwa, et al.
**BACKGROUND:** Tuberculous meningitis (TBM)-related deaths occur early, often within weeks after treatment initiation. Enhanced treatment early in the disease course with agents that effectively penetrate the central nervous system may improve outcomes in TBM. **METHODS:** We c…
Joseph Donovan, Nguyen Duc Bang, Huu Khanh Trinh Dong, Dang Trung Nghia Ho, Thi Anh Thu Nguyen, et al.
Adjunctive corticosteroids such as dexamethasone are recommended in tuberculous meningitis treatment, despite modest and heterogeneous survival benefit. Leukotriene A4 hydrolase (LTA4H) genotypes associate with distinct intracerebral inflammatory phenotypes and may determine cort…
Nida Khan, Muhammad Ahmar Khan, Naila Muzaffar, Ahmad Ismail, Abdul Ghafoor, et al.
**INTRODUCTION:** Pakistan has one of the largest burdens of rifampicin-resistant/ multidrug-resistant TB according to the global estimates. Novel all oral treatment regimens containing new antibiotics with reduced treatment duration are available. World Health Organization guide…